BioSpace News Archive

Globant (NYSE: GLOB), a digitally-native technology services company, today announced the launch of its Life Sciences Studio.

ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it has launched the initial public offering of 7,355,000 shares of its common shares.

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced financial results for the first quarter ended March 31, 2020.

Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced that Chris Linthwaite, President and Chief Executive Officer, and Vikram Jog, Chief Financial Officer, will present updates regarding Fluidigm’s business strategy and financial performance at the following upcoming investor conferences

Ultragenyx Pharmaceutical Inc. announced positive longer-term safety and efficacy data from the first three cohorts of the ongoing Phase 1/2 study of DTX301, an investigational adeno-associated virus gene therapy for the treatment of ornithine transcarbamylase deficiency.

BridgeBio Pharma, Inc., reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations.

DTx was one of 8 grantees selected out of more than 100 academic and company applicants worldwide

New Analysis from Phase III BIPARK-1 Study Evaluate the Efficacy of Once-Daily ONGENTYS® (opicapone) Compared to Entacapone in Patients with Parkinson’s Disease

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has received first regulatory approval from Germany’s BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) to initiate a phase 2 clinical trial of its selective oral DHODH inhibitor,

Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, reports financial results for the three months ended March 31, 2020 and provides an update on its business progress.